The hyperlipidemia market size has grown steadily in recent years. It will grow from $20.92 billion in 2025 to $21.59 billion in 2026 at a compound annual growth rate (CAGR) of 3.2%. The growth in the historic period can be attributed to rising prevalence of cardiovascular diseases, widespread use of statins, increased awareness of cholesterol management, sedentary lifestyles and dietary changes, aging population growth.
The hyperlipidemia market size is expected to see steady growth in the next few years. It will grow to $25.54 billion in 2030 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to increasing adoption of PCSK9 inhibitors, growth in familial hyperlipidemia diagnosis, expansion of personalized lipid therapies, rising demand for preventive cardiology, improving access to advanced treatments. Major trends in the forecast period include increasing adoption of combination lipid-lowering therapies, rising focus on early screening and preventive care, growing use of injectable biologics for high-risk patients, expansion of home-based and long-term lipid management, stronger emphasis on lifestyle-integrated treatment approaches.
Increasing incidences of chronic conditions such as heart disease are expected to drive the growth of the hyperlipidemia market going forward. Heart diseases encompass a range of conditions affecting the heart and its functions. Treatments for hyperlipidemia help patients manage heart disease by lowering the risk of heart attacks, preventing strokes, improving endothelial function, and reducing the need for invasive interventions. For instance, in April 2025, according to the Centers for Disease Control and Prevention (CDC), a US-based federal agency, approximately 194 million U.S. adults, or 76.4%, reported having at least one chronic condition in 2023. The prevalence was 59.5% among young adults, 78.4% among midlife adults, and 93% among older adults. Therefore, rising incidences of chronic disorders such as heart disease are driving the hyperlipidemia market.
Major companies operating in the hyperlipidemia market are focusing on developing innovative therapies, such as advanced low-density lipoprotein cholesterol (LDL-C)-lowering treatments, to strengthen their market positions. For example, in March 2024, Regeneron Pharmaceuticals, Inc., a US-based biotechnology company, announced U.S. Food & Drug Administration (FDA) approval of Praluent (alirocumab) Injection. This represents a significant advancement in treating heterozygous familial hypercholesterolemia (HeFH) in pediatric patients aged 8 and older, providing a targeted approach to manage dangerously high LDL-C levels. Phase 3 trials demonstrated a 31% reduction in LDL-C with regular dosing. Its safety profile, consistent with adult use, reassures families and healthcare providers, while its status as the first therapy targeting the genetically validated PCSK9 protein marks a milestone in heart disease treatment, positioning Praluent as a key option for managing high cholesterol in children with HeFH.
In June 2025, Eli Lilly and Company, a US-based biopharmaceutical firm, acquired Verve Therapeutics for up to $1.3 billion. Through this acquisition, Lilly aims to transform chronic cholesterol management by integrating Verve’s in vivo gene-editing platform, offering a potential one-time therapy for hyperlipidemia. Verve Therapeutics, a US-based clinical-stage company, develops base-editing medicines, including VERVE-102 targeting PCSK9, to durably lower LDL cholesterol and other lipoprotein drivers of atherosclerotic cardiovascular disease.
Major companies operating in the hyperlipidemia market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Co. Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Menarini Group, Dr. Reddy's Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Inc., Aspen Pharmacare Holdings Limited, Zydus Lifesciences Ltd.
North America was the largest region in the hyperlipidemia market in 2025. The regions covered in the hyperlipidemia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hyperlipidemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the hyperlipidemia market by increasing costs for imported active pharmaceutical ingredients, biologics, and injectable drug components, affecting pricing and supply stability. These impacts are more pronounced in regions reliant on cross-border pharmaceutical supply chains, including Asia-Pacific and parts of Latin America. However, tariffs are also encouraging local manufacturing, generic drug production, and regional sourcing strategies, supporting long-term market resilience and affordability.
The hyperlipidemia market research report is one of a series of new reports that provides hyperlipidemia market statistics, including hyperlipidemia industry global market size, regional shares, competitors with a hyperlipidemia market share, detailed hyperlipidemia market segments, market trends and opportunities, and any further data you may need to thrive in the hyperlipidemia industry. This hyperlipidemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Hyperlipidemia is a metabolic condition characterized by abnormally elevated levels of lipids, including cholesterol and triglycerides, in the blood. It is a common disorder and a major risk factor for cardiovascular diseases.
The main types of hyperlipidemia are familial and acquired. Familial hyperlipidemia is a genetic disorder marked by inherited high levels of lipids in the bloodstream, significantly increasing the risk of cardiovascular complications. Treatments for hyperlipidemia include statins, PCSK9 inhibitors, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, combination therapies, and other options. These treatments are administered via oral or parenteral routes. Hyperlipidemia therapies are distributed and used across various end-users, including hospitals, specialty clinics, home healthcare, and other healthcare facilities.
The hyperlipidemia market consists of revenues earned by entities by providing weight management, surgeries and combination therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The hyperlipidemia market also includes sales of niacin (nicotinic acid), omega-3 fatty acid supplements, ezetimibe, resins, adenosine triphosphate-citrate lyase (ACL) inhibitors, lomitapide and mipomersen. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The hyperlipidemia market size is expected to see steady growth in the next few years. It will grow to $25.54 billion in 2030 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to increasing adoption of PCSK9 inhibitors, growth in familial hyperlipidemia diagnosis, expansion of personalized lipid therapies, rising demand for preventive cardiology, improving access to advanced treatments. Major trends in the forecast period include increasing adoption of combination lipid-lowering therapies, rising focus on early screening and preventive care, growing use of injectable biologics for high-risk patients, expansion of home-based and long-term lipid management, stronger emphasis on lifestyle-integrated treatment approaches.
Increasing incidences of chronic conditions such as heart disease are expected to drive the growth of the hyperlipidemia market going forward. Heart diseases encompass a range of conditions affecting the heart and its functions. Treatments for hyperlipidemia help patients manage heart disease by lowering the risk of heart attacks, preventing strokes, improving endothelial function, and reducing the need for invasive interventions. For instance, in April 2025, according to the Centers for Disease Control and Prevention (CDC), a US-based federal agency, approximately 194 million U.S. adults, or 76.4%, reported having at least one chronic condition in 2023. The prevalence was 59.5% among young adults, 78.4% among midlife adults, and 93% among older adults. Therefore, rising incidences of chronic disorders such as heart disease are driving the hyperlipidemia market.
Major companies operating in the hyperlipidemia market are focusing on developing innovative therapies, such as advanced low-density lipoprotein cholesterol (LDL-C)-lowering treatments, to strengthen their market positions. For example, in March 2024, Regeneron Pharmaceuticals, Inc., a US-based biotechnology company, announced U.S. Food & Drug Administration (FDA) approval of Praluent (alirocumab) Injection. This represents a significant advancement in treating heterozygous familial hypercholesterolemia (HeFH) in pediatric patients aged 8 and older, providing a targeted approach to manage dangerously high LDL-C levels. Phase 3 trials demonstrated a 31% reduction in LDL-C with regular dosing. Its safety profile, consistent with adult use, reassures families and healthcare providers, while its status as the first therapy targeting the genetically validated PCSK9 protein marks a milestone in heart disease treatment, positioning Praluent as a key option for managing high cholesterol in children with HeFH.
In June 2025, Eli Lilly and Company, a US-based biopharmaceutical firm, acquired Verve Therapeutics for up to $1.3 billion. Through this acquisition, Lilly aims to transform chronic cholesterol management by integrating Verve’s in vivo gene-editing platform, offering a potential one-time therapy for hyperlipidemia. Verve Therapeutics, a US-based clinical-stage company, develops base-editing medicines, including VERVE-102 targeting PCSK9, to durably lower LDL cholesterol and other lipoprotein drivers of atherosclerotic cardiovascular disease.
Major companies operating in the hyperlipidemia market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Co. Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Menarini Group, Dr. Reddy's Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Inc., Aspen Pharmacare Holdings Limited, Zydus Lifesciences Ltd.
North America was the largest region in the hyperlipidemia market in 2025. The regions covered in the hyperlipidemia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hyperlipidemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs have influenced the hyperlipidemia market by increasing costs for imported active pharmaceutical ingredients, biologics, and injectable drug components, affecting pricing and supply stability. These impacts are more pronounced in regions reliant on cross-border pharmaceutical supply chains, including Asia-Pacific and parts of Latin America. However, tariffs are also encouraging local manufacturing, generic drug production, and regional sourcing strategies, supporting long-term market resilience and affordability.
The hyperlipidemia market research report is one of a series of new reports that provides hyperlipidemia market statistics, including hyperlipidemia industry global market size, regional shares, competitors with a hyperlipidemia market share, detailed hyperlipidemia market segments, market trends and opportunities, and any further data you may need to thrive in the hyperlipidemia industry. This hyperlipidemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Hyperlipidemia is a metabolic condition characterized by abnormally elevated levels of lipids, including cholesterol and triglycerides, in the blood. It is a common disorder and a major risk factor for cardiovascular diseases.
The main types of hyperlipidemia are familial and acquired. Familial hyperlipidemia is a genetic disorder marked by inherited high levels of lipids in the bloodstream, significantly increasing the risk of cardiovascular complications. Treatments for hyperlipidemia include statins, PCSK9 inhibitors, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, combination therapies, and other options. These treatments are administered via oral or parenteral routes. Hyperlipidemia therapies are distributed and used across various end-users, including hospitals, specialty clinics, home healthcare, and other healthcare facilities.
The hyperlipidemia market consists of revenues earned by entities by providing weight management, surgeries and combination therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The hyperlipidemia market also includes sales of niacin (nicotinic acid), omega-3 fatty acid supplements, ezetimibe, resins, adenosine triphosphate-citrate lyase (ACL) inhibitors, lomitapide and mipomersen. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Hyperlipidemia Market Characteristics
3. Hyperlipidemia Market Supply Chain Analysis
4. Global Hyperlipidemia Market Trends and Strategies
5. Hyperlipidemia Market Analysis of End Use Industries
7. Global Hyperlipidemia Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Hyperlipidemia Total Addressable Market (TAM) Analysis for the Market
9. Hyperlipidemia Market Segmentation
10. Hyperlipidemia Market Regional and Country Analysis
11. Asia-Pacific Hyperlipidemia Market
12. China Hyperlipidemia Market
13. India Hyperlipidemia Market
14. Japan Hyperlipidemia Market
15. Australia Hyperlipidemia Market
16. Indonesia Hyperlipidemia Market
17. South Korea Hyperlipidemia Market
18. Taiwan Hyperlipidemia Market
19. South East Asia Hyperlipidemia Market
20. Western Europe Hyperlipidemia Market
21. UK Hyperlipidemia Market
22. Germany Hyperlipidemia Market
23. France Hyperlipidemia Market
24. Italy Hyperlipidemia Market
25. Spain Hyperlipidemia Market
26. Eastern Europe Hyperlipidemia Market
27. Russia Hyperlipidemia Market
28. North America Hyperlipidemia Market
29. USA Hyperlipidemia Market
30. Canada Hyperlipidemia Market
31. South America Hyperlipidemia Market
32. Brazil Hyperlipidemia Market
33. Middle East Hyperlipidemia Market
34. Africa Hyperlipidemia Market
36. Hyperlipidemia Market Competitive Landscape and Company Profiles
37. Hyperlipidemia Market Other Major and Innovative Companies
40. Hyperlipidemia Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Hyperlipidemia Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses hyperlipidemia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for hyperlipidemia? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hyperlipidemia market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Familial Hyperlipidemia; Acquired Hyperlipidemia2) By Treatment: Statins; PCSK9 Inhibitors; Bile Acid Sequestrants; Cholesterol Absorption Inhibitors; Fibric Acid Derivatives; Combination; Other Treatments
3) By Route of Administration: Oral; Parenteral
4) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End Users
Subsegments:
1) By Familial Hyperlipidemia: Familial Hypercholesterolemia (FH); Familial Combined Hyperlipidemia; Familial Dysbetalipoproteinemia2) By Acquired Hyperlipidemia: Diet-Related Hyperlipidemia; Secondary Hyperlipidemia; Drug-Induced Hyperlipidemia
Companies Mentioned: Pfizer Inc.; Johnson and Johnson Limited; Merck and Co. Inc.; AbbVie Inc.; Bayer AG; Novartis AG; Sanofi-Aventis LLC.; Bristol-Myers Squibb Company; GlaxoSmithKline plc.; Eli Lilly and Co. Ltd.; Boehringer Ingelheim International GmbH; Teva Pharmaceutical Industries Ltd.; Daiichi Sankyo Company Limited; Sun Pharmaceutical Industries Limited; Otsuka Pharmaceutical Co. Ltd.; Menarini Group; Dr. Reddy's Laboratories Ltd.; Apotex Inc.; Hikma Pharmaceuticals PLC; Cipla Inc.; Aspen Pharmacare Holdings Limited; Zydus Lifesciences Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Hyperlipidemia market report include:- Pfizer Inc.
- Johnson and Johnson Limited
- Merck and Co. Inc.
- AbbVie Inc.
- Bayer AG
- Novartis AG
- Sanofi-Aventis LLC.
- Bristol-Myers Squibb Company
- GlaxoSmithKline plc.
- Eli Lilly and Co. Ltd.
- Boehringer Ingelheim International GmbH
- Teva Pharmaceutical Industries Ltd.
- Daiichi Sankyo Company Limited
- Sun Pharmaceutical Industries Limited
- Otsuka Pharmaceutical Co. Ltd.
- Menarini Group
- Dr. Reddy's Laboratories Ltd.
- Apotex Inc.
- Hikma Pharmaceuticals PLC
- Cipla Inc.
- Aspen Pharmacare Holdings Limited
- Zydus Lifesciences Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 21.59 Billion |
| Forecasted Market Value ( USD | $ 25.54 Billion |
| Compound Annual Growth Rate | 4.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 23 |
